Cited by 555Bone Metabolism and DiseasesBone and Dental Protein StudiesRheumatoid Arthritis Research and Therapies

Inhibition of Osteoblast Differentiation by Tumor Necrosis Factor-α*

Gilbert, Linda, He, Xiaofei, Farmer, Paul, Boden, Scott, Kozlowski, Mirek, Rubin, Janet, Nanes, Mark S.·2000·Endocrinology

Abstract

Tumor necrosis factor-alpha (TNF-alpha) has a key role in skeletal disease in which it promotes reduced bone formation by mature osteoblasts and increased osteoclastic resorption. Here we show that TNF inhibits differentiation of osteoblasts from precursor cells. TNF-alpha treatment of fetal calvaria precursor cells, which spontaneously differentiate to the osteoblast phenotype over 21 days, inhibited differentiation as shown by reduced formation of multilayered, mineralizing nodules and decreased secretion of the skeletal-specific matrix protein osteocalcin. The effect of TNF was dose dependent with an IC50 of 0.6 ng/ml, indicating a high sensitivity of these precursor cells. Addition of TNF-alpha from days 2-21, 2-14, 7-14, and 7-10 inhibited nodule formation but addition of TNF after day 14 had no effect. Partial inhibition of differentiation was observed with addition of TNF on only days 7-8, suggesting that TNF could act during a critical period of phenotype selection. Growth of cells on collagen-coated plates did not prevent TNF inhibition of differentiation, suggesting that inhibition of collagen deposition into matrix by proliferating cells could not, alone, explain the effect of TNF. Northern analysis revealed that TNF inhibited the expression of insulin-like growth factor I (IGF-I). TNF had no effect on expression of the osteogenic bone morphogenic proteins (BMPs-2, -4, and -6), or skeletal LIM protein (LMP-1), as determined by semiquantitative RT-PCR. Addition of IGF-I or BMP-6 to fetal calvaria precursor cell cultures enhanced differentiation but could not overcome TNF inhibition, suggesting that TNF acted downstream of these proteins in the differentiation pathway. The clonal osteoblastic cell line, MC3T3-E1-14, which acquires the osteoblast phenotype spontaneously in postconfluent culture, was also studied. TNF inhibited differentiation of MC3T3-E1-14 cells as shown by failure of mineralized matrix formation in the presence of calcium and phosphate. TNF was not cytotoxic to either cell type as shown by continued attachment and metabolism in culture, trypan blue exclusion, and Alamar Blue cytotoxicity assay. These results demonstrate that TNF-alpha is a potent inhibitor of osteoblast differentiation and suggest that TNF acts distal to IGF-I, BMPs, and LMP-1 in the progression toward the osteoblast phenotype.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endo.141.11.7739

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TNF-α has the capacity to inhibit osteoblastogenesis by downregulating expression of IGF-1 in mesenchymal stem cell precursors.

    “In addition, TNF-α has the capacity to inhibit osteoblastogenesis by downregulating the expression of IGF-1 in mesenchymal stem cell precursors [32].”

    From Osteoclasts and Microgravity (2020) · cites this paper as [32]

    The Abstract reports that TNF-α inhibits differentiation of fetal calvaria precursor cells and reduces IGF-I expression. But the Discussion says added IGF-I does not overcome the inhibition and places TNF-α’s action downstream of IGF-I; it does not support downregulation of IGF-I as the mechanism. The experiments used fetal calvaria precursors and a clonal osteoblastic cell line, not specifically identified mesenchymal stem cells. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Nanes MS, Rubin J, Titus L, Hendy GN, Catherwood B 1991 Tumor necrosis factor-␣ inhibits 1,25-dihydroxyvitamin D 3 -stimulated bone Gla protein syn- thesis in rat osteosarcoma cells (ROS 17/2.8) by a pretranslational mechanism. Endocrinology 128:2577-2582
  2. Stein GS, Lian JB, Stein JL, van Wijnen AJ, Frenkel B, Montecino M 1996 Mechanisms regulating osteoblast proliferation and differentiation. In: Bilez- ikian JP, Raisz LG, Rodan GA (eds) Principles of Bone Biology. Academic Press, New York, pp 69 -86

Cited by

Sorted by citations

Authors
Gilbert, L., He, X., Farmer, P., Boden, S., Kozlowski, M., Rubin, J., & Nanes, M. S.
Affiliations
Emory University (US)
Corresponding author
Nanes, Mark S.
Venue
Endocrinology
Published
2000-11-01
Volume
141
Issue
11
Pages
3956-3964
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2085016903
Cited by
555
References
4
Citations by year
2026: 22 · 2025: 25 · 2024: 19 · 2023: 32 · 2022: 35 · 2021: 25 · 2020: 26 · 2019: 23 · 2018: 31 · 2017: 26 · 2016: 29 · 2015: 36 · 2014: 30 · 2013: 21 · 2012: 25
FWCI
2.77
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • National Institutes of Health (5r01ar044228-03)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R01-AR44228)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Rheumatology › Bone and Dental Protein Studies
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
osteogenic differentiation, osteoblast precursors, osteocalcin, insulin-like growth factor I, bone morphogenetic proteins, BMP6, mineralization, bone formation, osteoclast resorption
MeSH terms
Animals, Ascorbic Acid, Bone and Bones, Calcium Phosphates, Carrier Proteins, Cell Differentiation, Cell Line, Cells, Cultured, Cytoskeletal Proteins, Insulin-Like Growth Factor I, Osteoblasts, Phosphates, RNA, Messenger, Tumor Necrosis Factor-alpha, Blotting, Northern, Gene Expression, Rats, Sprague-Dawley, Bone Morphogenetic Proteins, Reverse Transcriptase Polymerase Chain Reaction, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Rats, LIM Domain Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review